|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Soluble ST2:A new and promising activity marker in ulcerative colitis显示文摘AIM:To correlate circulating soluble ST2(sST2) levels with the severity of ulcerative colitis(UC) and serum levels of pro-inflammatory cytokines,and to demonstrate the predictive power of sST2 levels for differentiation between active and inactive UC.METHODS:We recruited 153 patients:82 with UC,26 with Crohn's disease(CD) and 43 disease controls [non-inflammatory bowel disease(IBD)].Subjects were excluded if they had diagnosis of asthma,autoimmune diseases or hypertension.The serum levels of sST2 and pro-inflammatory cytokines [pg/mL;median(25th-75th)] as well as clinical features,endoscopic and histological features,were subjected to analyses.The sST2 performance for discrimination between active and inactive UC,non-IBD and healthy controls(HC) was determined with regard to sensitivity and specificity,and Spearman's rank correlation coefficient(r).To validate the method,the area under the curve(AUC) of receiver-operator characteristic(ROC) was determined(AUC,95% CI) and the total ST2 content of the colonic mucosa in UC patients was correlated with circulating levels of sST2.RESULTS:The serum sST2 value was significantly higher in patients with active [235.80(90.65-367.90) pg/mL] rather than inactive UC [33.19(20.04-65.32) pg/mL],based on clinical,endoscopic and histopathological characteristics,as well as compared with non-IBD and HC(P < 0.001).The median level of sST2 in CD patients was 54.17(35.02-122.0) pg/mL,significantly higher than that of the HC group only(P < 0.01).The cutoff was set at 74.87 pg/mL to compare active with inactive UC in a multicenter cohort of patients.Values of sensitivity,specificity,and ability to correctly classify UC,according to activity,were 83.33%,83.33% and 83.33%,respectively.The AUC of the ROC curve to assess the ability of this molecule to discriminate between active vs inactive UC was 0.92(0.86-0.97,P < 0.0001).The serum levels of sST2 in patients with UC significantly correlated with endoscopic and histo-pathological scores(r = 0.76 and r = 0.67,P < 0.0001,respectively),and with the pro-inflammatory cytokine,tumor necrosis factor-α(r = 0.69 and r = 0.61,respectively,P < 0.0001).Interestingly,we found a direct correlation between total intestinal ST2 content and serum levels of sST2,adjusted to endoscopic activity score in patients with mild(r = 0.44,P = 0.004),moderate(r = 0.59,P = 0.002) and severe disease(r = 0.82,P = 0.002).Only patients with inactive UC showed no significant correlation(r = 0.45,P = 0.267).CONCLUSION:sST2 levels correlated with disease severity and inflammatory cytokines,are able to differentiate active from inactive UC and might have a role as a biomarker. | David Díaz-Jiménez Lucía E Núez Caroll J Beltrán Enzo Candia Cristóbal Suazo Manuel varez-Lobos María-Julieta González Marcela A Hermoso Rodrigo Quera | 2011 | World Journal of Gastroenterology2011，17，17： | 8 |
| 2 | Glucocorticosteroid therapy in inflammatory bowel diseases: From clinical practice to molecular biology显示文摘Inflammatory bowel diseases(IBDs),such as ulcerative colitis and Crohn's disease,are chronic pathologies associated with a deregulated immune response in the intestinal mucosa,and they are triggered by environmental factors in genetically susceptible individuals.Exogenous glucocorticoids(GCs)are widely used as anti-inflammatory therapy in IBDs.In the past,patients with moderate or severe states of inflammation received GCs as a first line therapy with an important effectiveness in terms of reduction of the disease activity and the induction of remission.However,this treatment often results in detrimental side effects.This downside drove the development of second generation GCs and more precise(non-systemic)drugdelivery methods.Recent clinical trials show that most of these new treatments have similar effectiveness to first generation GCs with fewer adverse effects.The remaining challenge in successful treatment of IBDs concerns the refractoriness and dependency that some patients encounter during GCs treatment.A deeper understanding of the molecular mechanisms underlying GC response is key to personalizing drug choice for IBDs patients to optimize their response to treatment.In this review,we examine the clinical characteristics of treatment with GCs,followed by an in depth analysis of the proposed molecular mechanisms involved in its resistance and dependence associated with IBDs.This thorough analysis of current clinical and biomedical literature may help guide physicians in determining a course of treatment for IBDs patients and identifies important areas needing further study. | Karen Dubois-Camacho Payton A Ottum Daniel Franco-Munoz Marjorie De la Fuente Alejandro Torres-Riquelme David Díaz-Jiménez Mauricio Olivares-Morales Gonzalo Astudillo Rodrigo Quera Marcela A Hermoso | 2017 | World Journal of Gastroenterology2017，23，36： | 6 |
| 3 | Inflammatory bowel disease: A descriptive study of 716 local Chilean patients显示文摘AIM: To demographically and clinically characterize inflammatory bowel disease(IBD) from the local registry and update data previously published by our group.METHODS: A descriptive study of a cohort based on a registry of patients aged 15 years or older who were diagnosed with IBD and attended the IBD program at Clínica Las Condes in Santiago, Chile. The registry was created in April 2012 and includes patients registered up to October 2015. The information was anonymously downloaded in a monthly report, and the information on patients with more than one visit was updated. The registry includes demographic, clinical and disease characteristics, including the Montreal Classification, medical treatment, surgeries and hospitalizations for crisis. Data regarding infection with Clostridium difficile(C. difficile) were incorporated in the registry in 2014. Data for patients who received consultations as second opinions and continued treatment at this institution were also analyzed. RESULTS: The study included 716 patients with IBD: 508 patients(71%) were diagnosed with ulcerative colitis(UC), 196 patients(27%) were diagnosed with Crohn's disease(CD) and 12 patients(2%) were diagnosed with unclassifiable IBD. The UC/CD ratio was 2.6/1. The median age was 36 years(range 16-88), and 58% of the patients were female, with a median age at diagnosis of 29 years(range 5-76). In the past 15 years, a sustained increase in the number of patients diagnosed with IBD was observed, where 87% of the patients were diagnosed between the years 2001 and 2015. In the cohort examined in the present study, extensive colitis(50%) and colonic involvement(44%) predominated in the patients with UC and CD, respectively. In CD patients, nonstricturing/non-penetrating behavior was more frequent(80%), and perianal disease was observed in 28% of the patients. There were significant differences in treatment between UC and CD, with a higher use of corticosteroids, and immunosuppressive and biological therapies was observed in the patients with CD(P < 0.05 and P < 0.01). Significant surgical differences were also observed: 5% of the UC patients underwent surgery, whereas 38% of the CD patients required at least one surgery(P < 0.01). The patients with CD were hospitalized more often during their disease course than the patients with UC(55% and 35% of the patients, respectively; P < 0.01). C. difficile infection was acquired by 5% of the patients in each group at some point during the disease course. Nearly half of the patients consulted at the institution for a second opinion, and 32% of these individuals continued treatment at the institution. CONCLUSION: IBD has continued to increase in the study cohort, slowly approaching the level reported in developed countries. | Daniela Simian Daniela Fluxá Lilian Flores Jaime Lubascher Patricio Ibánez Carolina Figueroa Udo Kronberg Raúl Acuna Mauricio Moreno Rodrigo Quera | 2016 | World Journal of Gastroenterology2016，22，22： | 2 |
| 4 | Bacteremia as an adverse event of fecal microbiota transplantation in a patient with Crohn’s disease and recurrent Clostridium difficile infection显示文摘 | Rodrigo Quera Ricardo Espinoza Camila Estay Daniela Rivera | 2013 | Journal of Crohn’s and Colitis2013，，： | 2 |
| 5 | Small intestinal bacterial overgrowth: roles of antibiotics, prebiotics, and probiotics显示文摘 | Eamonn M M Quigley E Y Quera R | 2006 | Gastroen Terology2006，，130： | 1 |
| 6 | Circadi- an rhythms, melatonin and depression 显示文摘 | QUERA SALVA MA HARTLEY S BARBOT F | 2011 | Curr Pharm Des2011，17，15： | 1 |
| 7 | Circadian rhythms, melatonin and depression 显示文摘 | QUERA SALVA MA HARTLEY S BARBOT F | 2011 | Curt Pharm Des2011，17，15： | 1 |
| 8 | Major depressive disorder, sleep EEG and agomelatine: an open-label study 显示文摘 | Quera Salva MA Vanier B Laredo J | 2007 | Int J Neuropsychopharmacol2007，10，5： | 1 |
| 9 | Risk factors for oxygen desaturation during sleep after abdominal surgery显示文摘 | Beydon L Hassapopoulos J Quera MA | 1992 | Br J Anaesth1992，69，2： | 1 |
| 10 | Thromboemlism-an important manifestation of inflammatory bowel disease 显示文摘 | Quera R shanahan F | 2004 | Am J Gastroenterol2004，99，10： | 1 |
| 11 | Small intestinal bacterial overgrowth : an update 显示文摘 | QUERA P R QUIGLEY E M MADRID S A M | 2005 | Rev Med Chil2005，133，11： | 1 |
| 12 | Small intestinal bacterial overgrowth: Roles of antibiotics, prebiotics, and probiotics显示文摘 | Quigley E Quera R | 2006 | Gastroenterology2006，130，2： | 1 |
| 13 | Predictors of Acute Esophagitis in Lung Cancer Patients Treated With Concurrent Three-Dimensional Conformal Radiotherapy and Chemotherapy显示文摘 | Núria Rodríguez Manuel Algara Palmira Foro Marti Lacruz Anna Reig Ismael Membrive Joan Lozano José Luis López Jaime Quera Enric Fernández-Velilla Xavier Sanz | 2009 | International Journal of Radiation Oncology, Biology, Physics2009，，： | 1 |
| 14 | Circadian rhythms, melatonin and depression 显示文摘 | M A Quera Salva S Hartley F Barbot | 2011 | Current Pharmaceutical Design2011，17，15： | 1 |
| 15 | Heparin and insulin treatment of acute pancreatitis caused by hypertrigly ceridemia, experience of 5 cases显示文摘 | BERGER Z QUERA R PONIACHIK J | 2001 | Rev Med Chil2001，129，12： | 1 |
| 16 | Major depressive disorder, sleep EEG and agomelatine : an open- label study 显示文摘 | Quera Salva MA Vanier B Laredo J | 2007 | Int J Neuropsychopharmacol2007，10，5： | 1 |
| 17 | Physician-patient dialogue surrounding patients' expression of coneern显示文摘 | Eide H Quera V Graugaard P | 2004 | Soc SciMed2004，，59： | 1 |
| 18 | Octreotide administration and/or endoscopic treatment in cirrhotic patients with acute variceal bleeding: a muhicentric study显示文摘 | SILVA G QUERA R FLUXA F | 2004 | Rev Med Chil2004，132，3： | 1 |
| 19 | Heparin and insulin treatment of acute pancreatitis caused by hypertriglyceridemia:experience of 5 cases显示文摘 | Berger Z Quera R Poniachik J | 2001 | Rev Med Chil2001，129，12： | 1 |
| 20 | Octreotide administration and/or endoscopic treatment in cirrhotic patients with acute variceal bleeding: a multicentric study 显示文摘 | Silva G Quera R Fluxa F | 2004 | Rev Med Chil2004，132，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员